Inventor

Klaus Charisse

Inventor

Acton, MA, US

Overview

2015–2021

Patent span

Human necessities

Primary field (CPC A)

Patents· 28 as inventor

Public. Assignee & technology derived from the patent record. Each patent links to its LexDana page.

C12Nprimary

C12NMicroorganisms or enzymes33%

A61KPreparations for medical, dental or toiletry purposes28%

A61PSpecific therapeutic activity of chemical compounds or medicinal preparations26%

C07HSugars8%

C07KPeptides3%

C12YEnzymes2%

PatentTitleYear

11,118,181Compositions and methods for inhibition of expression of protein C (PROC) genes2021 10,995,336Serpina1 iRNA compositions and methods of use thereof2021 10,988,768TMPRSS6 iRNA compositions and methods of use thereof2021 10,920,223Serpina1 iRNA compositions and methods of use thereof2021 10,913,950TMPRSS6 iRNA compositions and methods of use thereof2021 10,814,007Angiotensinogen (AGT) iRNA compositions and methods of use thereof2020 10,683,504Serpina1 iRNA compositions and methods of use thereof2020 10,668,170Modified RNAi agents2020 10,570,391RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases2020 10,273,478Compositions and methods for inhibition of expression of protein C (PROC) genes2019 10,238,749Angiotensinogen (AGT) iRNA compositions and methods of use thereof2019 10,125,369PCSK9 iRNA compositions and methods of use thereof2018 10,030,244Serpina1 iRNA compositions and methods of use thereof2018 9,970,006Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes2018 9,850,488Complement component C5 iRNA compositions and methods of use thereof2017 9,796,974'Modified RNAi agents'2017 9,783,806'TMPRSS6 iRNA compositions and methods of use thereof'2017 9,725,718'Compositions and methods for inhibition of expression of protein C (PROC) genes'2017 9,701,963'Complement component C5 iRNA compositions and methods of use thereof'2017 9,574,192'Serapina1 iRNA compositions and methods of use thereof'2017 9,399,775'RNAi agents, compositions and methods of use thereof for treating transthyretin (TTR) associated diseases'2016 9,376,680'Serpinc1 iRNA compositions and methods of use thereof'2016 9,315,813'Compositions and methods for inhibition of expression of apolipoprotein C-III (APOC3) genes'2016 9,249,415'Complement component C5 iRNA compositions and methods of use thereof'2016 9,228,188'Compositions and method for inhibiting hepcidin antimicrobial peptide (HAMP) or HAMP-related gene expression'2016 9,187,746'Dual targeting siRNA agents'2015 9,127,274'Serpinc1 iRNA compositions and methods of use thereof'2015 9,068,184'Compositions and methods for inhibition of expression of protein C (PROC) genes'2015

Career & activity timeline

Assembled from patent assignee/location history and declaration credentials.

2015–2021Patents assigned to ALNYLAM PHARMACEUTICALS INC (28)· patent assignee history

2015–2016Patents assigned to CHARISSE KLAUS (4)· patent assignee history

2015–2016Patents assigned to BETTENCOURT BRIAN (3)· patent assignee history

2015–2016Patents assigned to KUCHIMANCHI SATYANARAYANA (3)· patent assignee history

2015–2016Patents assigned to MILSTEIN STUART (3)· patent assignee history

2015–2021Based in Acton, MA, US· patent location history

2015–2020Based in Cambridge, MA, US· patent location history

Inventor activity

Assignee and location history derived from the patent record.

Assignees

Assignee	Patents	Span
ALNYLAM PHARMACEUTICALS INC	28	2015–2021
CHARISSE KLAUSself	4	2015–2016
BETTENCOURT BRIAN	3	2015–2016
KUCHIMANCHI SATYANARAYANA	3	2015–2016
MILSTEIN STUART	3	2015–2016

Locations

Location	Patents	Span
Acton, Massachusetts, US	23	2015–2021
Cambridge, Massachusetts, US	5	2015–2020